|
The record quarter marks a new growth phase for the global multi-asset broker.
DUBAI, UAE, April 28, 2026 /PRNewswire/ -- STARTRADER has revealed its highest quarterly trading volume to date. The global multi-asset broker achieved $3.145 trillion in total trading volume during Q1, marking a 340% increase from the same period last year and a 56.7% jump from Q4 2025. Notably, client trading account openings increased by 280% year-on-year.
The results speak to the trust STARTRADER has earned through years of consistent execution. Now, its rebranding gives that trust a sharper identity, capturing its growing global ambitions. 'Built on Trust. Driven by Growth.'
On this milestone, the CEO of STARTRADER, Mr. Peter Karsten, commented:
"These numbers reflect what happens when a strong infrastructure is guided by a clear direction. Crossing $3 trillion in a single quarter is a milestone, but what matters most to us is that the growth is broad-based, consistent, and built to last."
The first-quarter performance reflects the company's sustained expansion, with monthly trading volume averaging $1 trillion throughout the quarter. This shows that clients' activity remained consistent throughout the quarter, which reflects their deep confidence in its platforms and offers.
Key Q1 2026 metrics:
- Total Q1 2026 trading volume: $3.145 trillion
- Quarter-on-quarter growth: +56.7%
- Year-on-year growth: +340%
- Client trading accounts: +280% year-on-year
- Average monthly trading volume: $1 trillion
Earlier in the year, STARTRADER introduced a refined brand identity that reflects the pillars on which the brand functions. As a broker regulated by CMA, ASIC, FSCA, FSA, and FSC, STARTRADER operates across five jurisdictions with a firm commitment to transparency and reliability. Advanced trading tools, competitive conditions, and a seamless multi-platform experience complete the picture of a broker built for the long term.
This rebranding unifies what STARTRADER has always stood for, making it more cohesive, more ambitious, and better aligned with where the company is headed.
The Q1 results offer early validation that this repositioning is resonating with both existing clients, deepening their activity, and with new traders choosing STARTRADER for the first time.
STARTRADER's brand positioning extends beyond its trading platform. As an Official Partner of the NBA and the Porsche Carrera Cup Middle East, the company aligns itself with institutions defined by precision, performance, and global reach. These partnerships reflect the standard STARTRADER holds itself to, and signal its ambitions to a global audience.
About STARTRADER
STARTRADER is a global multi-asset broker empowering retail and institutional partners to access global markets through a range of platforms, including MetaTrader, STAR-APP, and STAR-COPY.
Regulated across five jurisdictions (CMA, ASIC, FSCA, FSA, and FSC), STARTRADER combines strong governance with a client-first approach, serving both retail clients and partners with a commitment to transparency, reliability, and long-term growth.
The record quarter marks a new growth phase for the global multi-asset broker.
DUBAI, UAE, April 28, 2026 /PRNewswire/ -- STARTRADER has revealed its highest quarterly trading volume to date. The global multi-asset broker achieved $3.145 trillion in total trading volume during Q1, marking a 340% increase from the same period last year and a 56.7% jump from Q4 2025. Notably, client trading account openings increased by 280% year-on-year.
The results speak to the trust STARTRADER has earned through years of consistent execution. Now, its rebranding gives that trust a sharper identity, capturing its growing global ambitions. 'Built on Trust. Driven by Growth.'
On this milestone, the CEO of STARTRADER, Mr. Peter Karsten, commented:
"These numbers reflect what happens when a strong infrastructure is guided by a clear direction. Crossing $3 trillion in a single quarter is a milestone, but what matters most to us is that the growth is broad-based, consistent, and built to last."
The first-quarter performance reflects the company's sustained expansion, with monthly trading volume averaging $1 trillion throughout the quarter. This shows that clients' activity remained consistent throughout the quarter, which reflects their deep confidence in its platforms and offers.
Key Q1 2026 metrics:
- Total Q1 2026 trading volume: $3.145 trillion
- Quarter-on-quarter growth: +56.7%
- Year-on-year growth: +340%
- Client trading accounts: +280% year-on-year
- Average monthly trading volume: $1 trillion
Earlier in the year, STARTRADER introduced a refined brand identity that reflects the pillars on which the brand functions. As a broker regulated by CMA, ASIC, FSCA, FSA, and FSC, STARTRADER operates across five jurisdictions with a firm commitment to transparency and reliability. Advanced trading tools, competitive conditions, and a seamless multi-platform experience complete the picture of a broker built for the long term.
This rebranding unifies what STARTRADER has always stood for, making it more cohesive, more ambitious, and better aligned with where the company is headed.
The Q1 results offer early validation that this repositioning is resonating with both existing clients, deepening their activity, and with new traders choosing STARTRADER for the first time.
STARTRADER's brand positioning extends beyond its trading platform. As an Official Partner of the NBA and the Porsche Carrera Cup Middle East, the company aligns itself with institutions defined by precision, performance, and global reach. These partnerships reflect the standard STARTRADER holds itself to, and signal its ambitions to a global audience.
About STARTRADER
STARTRADER is a global multi-asset broker empowering retail and institutional partners to access global markets through a range of platforms, including MetaTrader, STAR-APP, and STAR-COPY.
Regulated across five jurisdictions (CMA, ASIC, FSCA, FSA, and FSC), STARTRADER combines strong governance with a client-first approach, serving both retail clients and partners with a commitment to transparency, reliability, and long-term growth.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
STARTRADER Posts $3.145 Trillion in Q1 2026 Trading Volume, Up 340% Year-on-Year
- New office in Boston-Cambridge innovation hub to expand partnerships with healthcare and life sciences leaders
- Supported through a Korea Health Industry Development Institute global expansion program
- Strategic move expected to accelerate commercialization, clinical collaborations, and market access in the United States
BOSTON, April 28, 2026 /PRNewswire/ -- HoneyNaps, an AI-powered sleep healthcare company specializing in sleep diagnostics and digital sleep medicine, announced that it has been selected for the Boston C&D Office Residency Program (Pharmaceutical & Medical Device Track) under South Korea's 2026 Bio-health Global Expansion Support Program (K-VIP: Korea Bio-Health Value-up Innovation Program).
The initiative is administered by the Korea Health Industry Development Institute (KHIDI) under the Ministry of Health and Welfare and is part of the Korean government's broader strategy to strengthen the global competitiveness of domestic bio-health companies and support overseas market expansion.
HoneyNaps will relocate its existing Boston office and establish operations at the Cambridge Innovation Center (CIC), located in Kendall Square, Cambridge, Massachusetts.
Strategic Presence in the World's Leading Biotech Cluster
Kendall Square, located in the Boston-Cambridge area, is widely recognized as one of the world's most concentrated biotech and healthcare innovation ecosystems. The district is home to leading pharmaceutical companies, biotech startups, hospitals, research institutions, and venture capital firms.
Anchored by institutions such as Massachusetts Institute of Technology, the area offers a uniquely integrated environment where research and development, clinical validation, commercialization, and investment are closely connected.
For HoneyNaps, the move is expected to provide direct access to potential partners across healthcare, life sciences, and digital health sectors, while creating new opportunities for proof-of-concept projects, joint research, and strategic collaborations.
Accelerating U.S. Market Expansion
Through its new presence in Kendall Square, HoneyNaps plans to deepen relationships with hospitals, sleep centers, pharmaceutical companies, and healthcare innovators across the U.S. East Coast.
The company also intends to expand clinical and commercialization partnerships in sleep medicine, leveraging the region's globally connected healthcare network.
The residency program provides participating companies with office space, networking opportunities, local business events, and market-entry support. Additional services include consulting, strategic partnership development, and access to local innovation programs.
Executive Comment
Sean Ha (Taekyoung Ha), President of HoneyNaps USA, stated:
"We have been preparing for global expansion through our existing U.S. subsidiary in Boston and establishing a presence in Kendall Square marks an important next step in expanding both research collaborations and commercialization opportunities. Being part of the same ecosystem as companies such as Pfizer, Moderna, Novartis, and Eli Lilly and Company will help us accelerate partnerships in sleep disorder clinical trials and strengthen our global market position."
About HoneyNaps
HoneyNaps is a South Korea-based digital health company specializing in AI-driven sleep diagnostics, sleep disorder analytics, and next-generation sleep healthcare solutions. The company develops technologies that improve access, efficiency, and clinical accuracy in sleep medicine through artificial intelligence and scalable healthcare platforms.
For further information, please contact:
HoneyNaps USA, Inc.
Christine Kwon / Managing Director
Email: sleep@honeynaps.com
Address: 14th Floor, One Broadway, Cambridge, MA 02142
Website: www.honeynaps.com
BOSTON, April 28, 2026 /PRNewswire/ -- HoneyNaps, an AI-powered sleep healthcare company specializing in sleep diagnostics and digital sleep medicine, announced that it has been selected for the Boston C&D Office Residency Program (Pharmaceutical & Medical Device Track) under South Korea's 2026 Bio-health Global Expansion Support Program (K-VIP: Korea Bio-Health Value-up Innovation Program).
The initiative is administered by the Korea Health Industry Development Institute (KHIDI) under the Ministry of Health and Welfare and is part of the Korean government's broader strategy to strengthen the global competitiveness of domestic bio-health companies and support overseas market expansion.
HoneyNaps will relocate its existing Boston office and establish operations at the Cambridge Innovation Center (CIC), located in Kendall Square, Cambridge, Massachusetts.
Strategic Presence in the World's Leading Biotech Cluster
Kendall Square, located in the Boston-Cambridge area, is widely recognized as one of the world's most concentrated biotech and healthcare innovation ecosystems. The district is home to leading pharmaceutical companies, biotech startups, hospitals, research institutions, and venture capital firms.
Anchored by institutions such as Massachusetts Institute of Technology, the area offers a uniquely integrated environment where research and development, clinical validation, commercialization, and investment are closely connected.
For HoneyNaps, the move is expected to provide direct access to potential partners across healthcare, life sciences, and digital health sectors, while creating new opportunities for proof-of-concept projects, joint research, and strategic collaborations.
Accelerating U.S. Market Expansion
Through its new presence in Kendall Square, HoneyNaps plans to deepen relationships with hospitals, sleep centers, pharmaceutical companies, and healthcare innovators across the U.S. East Coast.
The company also intends to expand clinical and commercialization partnerships in sleep medicine, leveraging the region's globally connected healthcare network.
The residency program provides participating companies with office space, networking opportunities, local business events, and market-entry support. Additional services include consulting, strategic partnership development, and access to local innovation programs.
Executive Comment
Sean Ha (Taekyoung Ha), President of HoneyNaps USA, stated:
"We have been preparing for global expansion through our existing U.S. subsidiary in Boston and establishing a presence in Kendall Square marks an important next step in expanding both research collaborations and commercialization opportunities. Being part of the same ecosystem as companies such as Pfizer, Moderna, Novartis, and Eli Lilly and Company will help us accelerate partnerships in sleep disorder clinical trials and strengthen our global market position."
About HoneyNaps
HoneyNaps is a South Korea-based digital health company specializing in AI-driven sleep diagnostics, sleep disorder analytics, and next-generation sleep healthcare solutions. The company develops technologies that improve access, efficiency, and clinical accuracy in sleep medicine through artificial intelligence and scalable healthcare platforms.
For further information, please contact:
HoneyNaps USA, Inc.
Christine Kwon / Managing Director
Email: sleep@honeynaps.com
Address: 14th Floor, One Broadway, Cambridge, MA 02142
Website: www.honeynaps.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
HoneyNaps Expands into Boston's Kendall Square, Accelerating Global Partnerships in AI Sleep Healthcare
